Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
Under what circumstances would you choose palopegteriparatide over teriparatide in patients with chronic hypoparathyroidism?
Related Questions
Do oral contraceptives lower bone mineral density in women with hypothalamic amenorrhea by lowering IGF-1?
Would you expect cinacalcet to lower calcium levels in a patient with Familial Hypocalciuric Hypercalcemia (FHH)?
In a patient with severe osteoporosis (T-score -3.9) and multiple vertebral fractures in the setting of multiple myeloma with bone involvement, would you consider adding an anabolic agent such as romosozumab or teriparatide despite concerns about osteosarcoma risk?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
How do you counsel patients on the risks and benefits of strontium supplements for osteoporosis management?
Would you favor oral bisphosphonates over intravenous formulations for patients with hormone sensitive prostate cancer and androgen deprivation therapy (ADT) related osteopenia?
Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?
Which fracture sites outside of the classical spine and hip are considered to be osteoporotic fractures even in the absence of a bone density diagnosis?
Is there a role for calcitriol in dialysis patients regardless of PTH level?
What range of musculoskeletal complaints have you seen with romosozumab use?
